{"product_id":"elekta-pestle-analysis","title":"Elekta PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSkip the Research. Get the Strategy.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eGain a strategic edge with our concise PESTLE analysis of Elekta—three to five key sentences reveal how political, economic, and technological shifts shape its trajectory. Ideal for investors and strategists needing quick actionable insight. Purchase the full report to access the complete, editable breakdown and deeper risk\/opportunity forecasts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealth policy priorities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNational cancer plans channel capital: GLOBOCAN reported 19.3 million new cancer cases in 2020 and EU Beating Cancer Plan allocates about 4 billion EUR to cancer control, boosting demand for radiation infrastructure. Shifts to value-based care—about 35% of US payments tied to quality metrics pre-2020—favor technologies that improve outcomes and throughput. Emphasis on early detection increases treatment volumes, while sudden policy reprioritizations can delay capital purchases.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eReimbursement and funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGovernment-set tariffs and DRGs directly shape economics for linac, Gamma Knife and brachytherapy; with about 50% of cancer patients requiring radiotherapy, reimbursement rates drive hospital adoption and ROI. Changes favoring hypofractionation or stereotactic care (reducing fractions per patient by up to 50%) shift demand toward high-precision devices. Public budget cycles dictate procurement timing, and austerity can suspend tenders for months or longer.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProcurement and tendering\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCentralized public tenders dominate major markets, with public procurement representing roughly 12% of global GDP (World Bank) and comprising over 50% of hospital equipment purchases in many EU states; compliance with local content and pricing rules is mandatory. Long evaluation cycles (commonly 6–18 months) and political oversight add uncertainty. Favorable domestic preferences advantage local competitors, so strict adherence to transparent tender laws is critical to win rates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrade policy and sanctions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTariffs and export controls on high-energy radiotherapy equipment, governed by regimes such as the Wassenaar Arrangement, raise delivery costs and can delay shipments when dual-use licensing is required; geopolitical sanctions (eg, restrictions on Russia\/Crimea since 2014) further limit market access. Licensing for dual-use components often adds weeks to lead times. Elekta operates in 120+ countries, so diversified manufacturing and alternative routing reduce exposure.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTariffs increase unit costs and margins pressure\u003c\/li\u003e\n\u003cli\u003eDual-use licenses add weeks to lead times\u003c\/li\u003e\n\u003cli\u003eSanctions restrict sales in targeted regions\u003c\/li\u003e\n\u003cli\u003eDiversified production across regions mitigates risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare digitization agendas\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpgovernment pushes for interoperable health it accelerate oncology software adoption with the eu digital europe programme allocating billion to scale secure platforms that favour vendors like elekta.\u003e\n\u003cpnational cloud and data rules in over of countries force on or private deployments shaping elekta go hosting costs.\u003e\n\u003cppublic funding for hospital digitalization national grants in can fast elekta software penetration but misalignment with local interoperability standards stall procurement and integration.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInteroperability push: EU Digital Europe €7.5B\u003c\/li\u003e\n\u003cli\u003eData sovereignty: \u0026gt;60% countries require residency\u003c\/li\u003e\n\u003cli\u003eFunding tailwinds: multi‑billion national grants 2023–24\u003c\/li\u003e\n\u003cli\u003eRisk: standards misalignment stalls projects\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/ppublic\u003e\u003c\/pnational\u003e\u003c\/pgovernment\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolicy funding \u003cstrong\u003e€7.5B\u003c\/strong\u003e and public procurement drive precision radiotherapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNational cancer plans and EU\/US funding (EU Digital Europe €7.5B) and rising value‑based care (≈35% US pay tied to quality pre‑2020) boost demand for precision radiotherapy; Elekta in 120+ countries. Public procurement (~12% global GDP) and reimbursement (≈50% cancer patients need radiotherapy) drive adoption; tariffs, dual‑use licenses and data‑sovereignty (\u0026gt;60% countries) add delivery and hosting complexity.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003cth\u003eEffect\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarkets\u003c\/td\u003e\n\u003ctd\u003e120+ countries\u003c\/td\u003e\n\u003ctd\u003eDiversifies risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFunding\u003c\/td\u003e\n\u003ctd\u003e€7.5B (EU)\u003c\/td\u003e\n\u003ctd\u003eSoftware uptake\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProcurement\u003c\/td\u003e\n\u003ctd\u003e~12% GDP\u003c\/td\u003e\n\u003ctd\u003eLong cycles\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how macro-environmental factors affect Elekta across Political, Economic, Social, Technological, Environmental and Legal dimensions, with data-backed trends and region-specific regulatory context. Designed for executives and investors, it highlights threats, opportunities and forward-looking scenarios in clean, insert-ready format to support strategy and funding decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise, visually segmented Elekta PESTLE that distills external risks and opportunities into an editable, shareable summary suitable for PowerPoints, meetings, and on-the-go review—helping teams and consultants align quickly and drive informed strategic discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCapital spending cycles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOncology equipment is high-ticket and closely tied to hospital CapEx cycles, so economic downturns commonly defer replacements and delay new cancer center builds. Stimulus programs and targeted healthcare funding can create short-term order spikes, while chronic underinvestment and an aging installed base sustain replacement demand. WHO projects 19.3 million new cancer cases in 2020 rising toward 28.4 million by 2040, underpinning long-term equipment need.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInterest rates and financing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eElevated policy rates—US federal funds 5.25–5.50% (June 2025), ECB deposit 4.00%, Bank of England 5.25%—push up leasing costs and hospital hurdle rates for capex. Vendor financing terms therefore become a commercial differentiator as suppliers can spread higher funding costs. Prospective rate cuts could unlock pent-up demand. Currency hedging choices must align with financing tenor and currency exposure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eElekta’s Swedish HQ and sales in over 120 countries expose it to SEK, USD, EUR and EMFX swings; the firm reported net sales of SEK 17.6bn in FY2024, with roughly two‑thirds generated outside the Nordic region. Currency mismatches between costs and revenues compress margins when SEK moves; hedging programs trim but do not eliminate quarterly P\u0026amp;L noise. Strong pricing power in oncology equipment and service contracts helps offset adverse FX moves.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInput costs and supply chain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpinput costs for semiconductors precision metals and logistics continue to drive elekta cogs extend lead times with chip easing about weeks in versus peaks above\u003e\n\u003cpinflation pressures cpi in force pricing actions and product redesigns to protect margins.\u003e\n\u003cpdual-sourcing and nearshoring initiatives have reduced exposure improved resiliency but prolonged component shortages still risk delivery delays revenue timing impacts.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCOGS drivers: semiconductors, precision metals, freight\u003c\/li\u003e\n\u003cli\u003eLead times: ~20 weeks (chip market 2024)\u003c\/li\u003e\n\u003cli\u003eInflation: ~3.5% global CPI 2024\u003c\/li\u003e\n\u003cli\u003eMitigation: dual-sourcing, nearshoring\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pdual-sourcing\u003e\u003c\/pinflation\u003e\u003c\/pinput\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmerging market growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpemerging markets face rising cancer burdens globocan recorded new cases globally and ems account for the fastest growth driving unmet demand radiotherapy oncology equipment.\u003e\n\u003cp\u003eBudget-constrained buyers favor cost-effective, robust systems and pay-per-service models; local financing and service networks are critical for uptake; FX and political risk commonly add 200–500 bps to required returns.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRising incidence: GLOBOCAN 2020: 19.3m cases\u003c\/li\u003e\n\u003cli\u003eUnder-penetration: high unmet radiotherapy need in EMs\u003c\/li\u003e\n\u003cli\u003eLocal finance \u0026amp; service critical\u003c\/li\u003e\n\u003cli\u003eFX\/political risk: +200–500 bps return premium\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pemerging\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePolicy funding \u003cstrong\u003e€7.5B\u003c\/strong\u003e and public procurement drive precision radiotherapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eElekta sales (SEK 17.6bn FY2024) are sensitive to hospital CapEx cycles; higher policy rates (Fed 5.25–5.50% Jun 2025) raise leasing costs and slow orders, while vendor financing becomes a commercial edge. FX exposure (two‑thirds revenue outside Nordics) and input inflation (~3.5% global CPI 2024) compress margins despite pricing power. EM cancer growth (GLOBOCAN 2020: 19.3m; 2040 proj. 28.4m) sustains long‑term demand.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFY2024 sales\u003c\/td\u003e\n\u003ctd\u003eSEK 17.6bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFed rate Jun 2025\u003c\/td\u003e\n\u003ctd\u003e5.25–5.50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal CPI 2024\u003c\/td\u003e\n\u003ctd\u003e~3.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChip lead time 2024\u003c\/td\u003e\n\u003ctd\u003e~20 weeks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCancer cases 2020 \/ 2040\u003c\/td\u003e\n\u003ctd\u003e19.3m \/ 28.4m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eElekta PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Elekta PESTLE Analysis document you’ll receive after purchase—fully formatted and ready to use. The layout, content, and structure visible in this preview are identical to the file you’ll download immediately after payment. No placeholders or teasers—this is the final, professionally structured analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"PortersFiveForce","offers":[{"title":"Default Title","offer_id":56162715664761,"sku":"elekta-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0914\/5276\/8633\/files\/elekta-pestle-analysis.png?v=1762707459","url":"https:\/\/portersfiveforce.com\/products\/elekta-pestle-analysis","provider":"Porter's Five Forces","version":"1.0","type":"link"}